And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still being discussed, but we hope to hang a bit with our short person, catch up on our reading, and have a listening party with Mrs. Pharmalot. And what about you? The time for a summer getaway is nigh, so you can whip up something fun. You could also hit the pause button and catch up on some reading or station yourself in front of the telly. Or you could use this as an opportunity to touch base with someone special and take stock of what matters. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
Two children have died from acute liver failure after being administered Zolgensma, a pricey gene therapy sold by Novartis to treat a rare disease, STAT reports. The company this week began notifying physicians and payers about the deaths, which occurred over the past few months in Russia and Kazakhstan. Although acute liver failure is noted in the product labeling information, a Novartis spokesperson acknowledged these episodes marked the first fatal cases attributed to the side effect. There were no deaths tied to acute liver failure in clinical trials for the medicine, which is used to treat spinal muscular atrophy, a genetic disorder that causes muscle wasting and weakness.
A sharp fall in share prices of several pharmaceutical companies prompted GSK to issue a statement aimed at countering concerns around impending litigation over the Zantac heartburn drug, The Wall Street Journal notes. After its stock fell 10%, GSK argued litigation related to Zantac is “inconsistent with the scientific consensus” and that there is no evidence of a causal association between the heartburn drug and the development of cancer. Zantac was voluntarily recalled in the U.S. in 2019 amid concerns it may contain small amounts of a probable human carcinogen, NDMA, and was ordered withdrawn in 2020. The first trial is set to begin on Aug. 22 against more than a dozen sellers.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect